Pneumagen is developing a glycan targeted intranasally delivered therapy for the pan-viral, universal treatment of infectious diseases of the respiratory tract

Latest news

12 May, 2022
Pneumagen Announces Positive Top Line Results from Phase 1 Study Evaluating Neumifil, a Product Designed for the Prevention and Treatment of Viral Respiratory Tract Infections
09 May, 2022
Pneumagen Announces Appointment of John Beadle as Non-Executive Director
13 Apr, 2022
Pneumagen to present on further significant development for its lead product, Neumifil at BioTrinity 2022

Meet the team